BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 10859074)

  • 1. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum.
    Whiteford MH; Whiteford HM; Yee LF; Ogunbiyi OA; Dehdashti F; Siegel BA; Birnbaum EH; Fleshman JW; Kodner IJ; Read TE
    Dis Colon Rectum; 2000 Jun; 43(6):759-67; discussion 767-70. PubMed ID: 10859074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
    Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
    Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels.
    Libutti SK; Alexander HR; Choyke P; Bartlett DL; Bacharach SL; Whatley M; Jousse F; Eckelman WC; Kranda K; Neumann RD; Carrasquillo JA
    Ann Surg Oncol; 2001 Dec; 8(10):779-86. PubMed ID: 11776491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study.
    van Kouwen MC; Nagengast FM; Jansen JB; Oyen WJ; Drenth JP
    J Clin Oncol; 2005 Jun; 23(16):3713-7. PubMed ID: 15923568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
    Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
    Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
    Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
    Smith FW; Heys SD; Evans NT; Roeda D; Gvozdanovic D; Eremin O; Mallard JR
    Nucl Med Commun; 1992 Mar; 13(3):193-5. PubMed ID: 1313554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients.
    Fiebrich HB; Brouwers AH; Koopmans KP; de Vries EG
    Eur J Cancer; 2009 Sep; 45(13):2312-5. PubMed ID: 19477116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer.
    Iagaru A; Masamed R; Singer PA; Conti PS
    Mol Imaging Biol; 2006; 8(5):309-14. PubMed ID: 16758370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-avid presacral soft tissue mass in previously treated rectal cancer: Diagnostic outcome and additional value of MRI, including diffusion-weighted imaging.
    Pennings JP; de Haas RJ; Murshid KJA; de Jong KP; Dierckx RAJO; Kwee TC
    Eur J Surg Oncol; 2019 Apr; 45(4):606-612. PubMed ID: 30594404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of 2-fluoro-2-deoxy-D-glucose positron emission tomography in managing patients of colorectal cancer with unexplained carcinoembryonic antigen elevation at different levels.
    Liu FY; Chen JS; Changchien CR; Yeh CY; Liu SH; Ho KC; Yen TC
    Dis Colon Rectum; 2005 Oct; 48(10):1900-12. PubMed ID: 15991059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer.
    Umesaki N; Tanaka T; Miyama M; Kawabe J; Okamura T; Koyama K; Ochi H; Ogita S
    Oncol Rep; 2000; 7(6):1261-4. PubMed ID: 11032926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery.
    Risum S; Høgdall C; Markova E; Berthelsen AK; Loft A; Jensen F; Høgdall E; Roed H; Engelholm SA
    Int J Gynecol Cancer; 2009 May; 19(4):600-4. PubMed ID: 19509556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bone and 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer.
    Gayed I; Vu T; Johnson M; Macapinlac H; Podoloff D
    Mol Imaging Biol; 2003; 5(1):26-31. PubMed ID: 14499159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
    Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
    J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
    Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
    Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of positron emission tomography in sarcomas.
    Schuetze SM
    Curr Opin Oncol; 2006 Jul; 18(4):369-73. PubMed ID: 16721133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.